Zydus Cadila gets USFDA approval to market generic schizophrenia drug Perphenazine

Zydus Cadila said it has 284 approvals and has so far filed over 386 abbreviated new drug applications (ANDAs) since the commencement of its filing process in the financial year 2003-2004.

FP Trending April 08, 2020 13:21:11 IST
Zydus Cadila gets USFDA approval to market generic schizophrenia drug Perphenazine

Pharma company Zydus Cadila has said it has received final approval from United States Food and Drug Administration (USFDA) to market generic Perphenazine tablets, used in the treatment of schizophrenia.

The drug is also used for the control of severe nausea and vomiting in adults.

USFDA has given its final nod to the company to market Perphenazine tablets USP in the strengths of 2 mg, 4 mg, 8 mg and 16 mg, Zydus Cadila said in a statement.

Zydus Cadila gets USFDA approval to market generic schizophrenia drug Perphenazine

Representative image. Image source: Pixabay

The USFDA is tasked with promoting public health through the control and supervision of several verticals including over-the-counter pharmaceutical drugs, vaccines, biopharmaceuticals and others.

“The drug will be manufactured at the group’s formulation manufacturing facility at Baddi [,” the statement added.

Zydus Cadila said it has 284 approvals and has so far filed over 386 abbreviated new drug applications (ANDAs) since the commencement of its filing process in the financial year 2003-2004.

On Tuesday, the pharma major announced on Twitter that it is producing Hydroxychloroquine, in large quantities to be used in the “treatment of coronavirus.” The company also said that it is working on developing a vaccine which will be a long term solution for COVID-19.

India on Tuesday decided to partially lift the ban on Hydroxychloroquine export, news agency PTI reported quoting officials.

US President Donald Trump had requested Prime Minister Narendra Modi to release the amount of Hydroxychloroquine ordered by the US after India on 25 March banned the export of the drug.

Updated Date:

also read

WHO seeks deeper cooperation from China on origins of COVID-19
World

WHO seeks deeper cooperation from China on origins of COVID-19

The phone call between WHO head Tedros Adhanom Ghebreyesus and Minister Ma Xiaowei came on the same day as China announced that nearly 60,000 COVID-19 deaths were reported since the country lifted its strict 'Zero Covid Policy' on 7 December

Will lift more Covid curbs after Lunar New Year, says Hong Kong health minister
World

Will lift more Covid curbs after Lunar New Year, says Hong Kong health minister

Secretary for Health Lo Chung-mau says curbs easing to go ahead despite expected surge in cases after holiday, arguing city has strong immunity levels to combat virus

Year of COVID-19? Will the Lunar New Year trigger another spike in China?
World

Year of COVID-19? Will the Lunar New Year trigger another spike in China?

It is expected that the Lunar New Year holiday travel rush – known as Chunyun – can drive a new wave of infections in China, especially in its vulnerable countryside. Last week, Xi Jinping also acknowledged concerns about a COVID-19 spike in rural China